Literature DB >> 2575973

Profile of an ideal antianginal agent.

E J Lazar1, W H Frishman.   

Abstract

Many antianginal agents are available for the treatment of coronary artery disease. These agents act by influencing the determinants of myocardial oxygen supply and demand. The 3 main classes of agents are the nitrates, beta-adrenergic blocking agents and the calcium entry blockers. Agents from all 3 classes have shown efficacy in treating both symptomatic and asymptomatic myocardial ischaemia. However, some patients cannot be treated with these agents because of side effects or contraindications. An ideal antianginal drug should effectively treat both angina and silent ischaemia. Additionally, it should be free of side effects, allow for maintenance of physical performance and be metabolically neutral. New agents are being developed which strive for this goal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575973     DOI: 10.2165/00003495-198900382-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  66 in total

Review 1.  Myocardial ischemia (first of three parts).

Authors:  L D Hillis; E Braunwald
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

2.  Platelet function in hyperlipoproteinemia.

Authors:  A C Carvalho; R W Colman; R S Lees
Journal:  N Engl J Med       Date:  1974-02-21       Impact factor: 91.245

Review 3.  Inhibition of the adrenergic nervous system in the treatment of angina pectoris.

Authors:  S E Epstein; E Braunwald
Journal:  Med Clin North Am       Date:  1968-09       Impact factor: 5.456

4.  Oxygen and vascular smooth muscle contraction.

Authors:  R Detar; D F Bohr
Journal:  Am J Physiol       Date:  1968-02

5.  Coronary artery syndromes after sudden propranolol withdrawal.

Authors:  E L Alderman; D J Coltart; G E Wettach; D C Harrison
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

6.  Reversal of diuretic-induced increases in serum low-density-lipoprotein cholesterol by the betablocker pindolol.

Authors:  H Schiffl; P Weidmann; R Mordasini; W Riesen; C Bachmann
Journal:  Metabolism       Date:  1982-04       Impact factor: 8.694

7.  Methemoglobin levels produced by organic nitrates in patients with coronary artery disease.

Authors:  E Arsura; E Lichstein; V Guadagnino; V Nicchi; M Sanders; G Hollander; A Greengart
Journal:  J Clin Pharmacol       Date:  1984-04       Impact factor: 3.126

8.  Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk.

Authors:  M H Weinberger
Journal:  Am J Med       Date:  1986-02-14       Impact factor: 4.965

9.  Tolerance to organic nitrates: clinical and experimental perspectives.

Authors:  P W Armstrong; J A Moffat
Journal:  Am J Med       Date:  1983-06-27       Impact factor: 4.965

10.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

View more
  1 in total

1.  Combination treatment with trimetazidine and diltiazem in stable angina pectoris.

Authors:  S C Manchanda; S Krishnaswami
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.